SCHEMBL21611949

SCHEMBL21611949

CC(C)Oc1ncc(-c2ncc(CNc3ccnc(C(F)(F)F)c3)cn2)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 4/20 0.55
▸ CYP2C9 P11712 2/20 0.55
▸ KCNH2 Q12809 1/20 0.37
▸ USP1 O94782 1/20 0.37
▸ WDR48 Q8TAF3 1/20 0.37
▸ HDAC4 P56524 4/20 0.36
▸ HDAC1 Q13547 3/20 0.36
▸ HDAC6 Q9UBN7 3/20 0.36
▸ VNN1 O95497 1/20 0.36
▸ CYP3A4 P08684 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ S1PR1 P21453 3/20 0.35
▸ S1PR5 Q9H228 2/20 0.35
▸ S1PR3 Q99500 1/20 0.35
▸ SMARCA2 P51531 1/20 0.34
▸ SMARCA4 P51532 1/20 0.34
▸ IDH1 O75874 1/20 0.34
▸ IDH2 P48735 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21614646 0.86 CYP2C19 (0.70) CYP2C19CYP2C9KCNH2USP1WDR48
SCHEMBL21614656 0.83 CYP2C19 (0.52) CYP2C19CYP2C9KCNH2USP1WDR48
SCHEMBL21611985 0.75 CYP2C19 (0.70) CYP2C19CYP2C9KCNH2HDAC1HDAC6
SCHEMBL21611920 0.74 CYP2C19 (0.54) CYP2C19CYP2C9KCNH2S1PR1S1PR3
SCHEMBL21612034 0.74 CYP2C19 (0.49) CYP2C19CYP2C9HDAC1HDAC6CYP3A4
SCHEMBL21611930 0.73 CYP2C9 (0.42) CYP2C19CYP2C9HDAC1HDAC6CYP3A4
SCHEMBL21614661 0.72 CYP2C19 (0.57) CYP2C19CYP2C9USP1WDR48HDAC1
SCHEMBL21614716 0.70 CYP2C19 (0.48) CYP2C19CYP2C9CYP3A4CYP1A2SMARCA2
SCHEMBL21611953 0.70 VNN1 (0.40) CYP2C19CYP2C9USP1WDR48HDAC4
SCHEMBL30060485 0.70 CYP2C19 (0.49) CYP2C19CYP2C9KCNH2S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 CYP2C19 1824/4885CYP2C9 2997/4885KCNH2 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback